Table 4 Outcomes for active controlled trials in bipolar mania (<6 weeks and 6–12 weeks)
From: Atypical antipsychotics in bipolar disorder: systematic review of randomised trials
| Â | Â | Events/total patients | Event rate (%) | Â | Â | ||
|---|---|---|---|---|---|---|---|
Outcome | Trials | Treatment | Active control | Treatment | Active control | Relative Risk (95% CI) | NNT (95% CI) |
Less than 6 weeks [37, 42, 43] | Â | Â | Â | Â | Â | Â | Â |
Efficacy | Â | Â | Â | Â | Â | Â | Â |
All mono- and adjunctive therapy | 3 | 242/487 | 227/466 | 50 | 49 | 1.0 (0.9 to 1.2) | not calculated |
Symptomatic remission | Â | Â | Â | Â | Â | Â | Â |
All mono- and adjunctive therapy | 3 | 137/333 | 126/322 | 41 | 39 | 1.1 (0.9 to 1.3) | not calculated |
Discontinuations | Â | Â | Â | Â | Â | Â | Â |
All cause | 4 | 75/346 | 90/338 | 22 | 27 | 0.8 (0.6 to 1.1) | not calculated |
Lack of efficacy | 3 | 19/331 | 17/323 | 5.7 | 5.3 | 1.1 (0.6 to 2.1) | not calculated |
Adverse events | 4 | 21/346 | 15/338 | 6.1 | 4.4 | 1.4 (0.7 to 2.6) | not calculated |
6 to 12 weeks [40-44] | Â | Â | Â | Â | Â | Â | Â |
Efficacy | Â | Â | Â | Â | Â | Â | Â |
All mono- and adjunctive therapy | 4 | 394/616 | 353/585 | 64 | 60 | 1.1 (0.97 to 1.2) | not calculated |
Symptomatic remission | Â | Â | Â | Â | Â | Â | Â |
All mono- and adjunctive therapy | 4 | 335/616 | 280/585 | 54 | 48 | 1.1 (1.01 to 1.3) | 15 (8.2 to 110) |
Emergence of depression | Â | Â | Â | Â | Â | Â | Â |
All mono- and adjunctive therapy | 4 | 40/510 | 62/492 | 7.8 | 13 | 0.6 (0.4 to 0.9) | 21 (12 to 99) |
Discontinuations | Â | Â | Â | Â | Â | Â | Â |
All cause | 5 | 300/675 | 346/651 | 44 | 53 | 0.8 (0.8 to 0.9) | 11 (7.1 to 30) |
Lack of efficacy | 5 | 119/675 | 94/651 | 18 | 14 | 1.2 (0.95 to 1.6) | not calculated |
Adverse events | 5 | 68/675 | 132/651 | 10 | 20 | 0.5 (0.4 to 0.7) | 9.8 (7.1 to 16) |